Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study

Diego J. Maselli; Surya P. Bhatt; Antonio Anzueto; Russell P. Bowler; Dawn L. DeMeo; Alejandro A. Diaz; Mark T. Dransfield; Ashraf Fawzy; Marilyn G. Foreman; Nicola A. Hanania; Craig P. Hersh; Victor Kim; Gregory L. Kinney; Nirupama Putcha; Emily S. Wan; J. Michael Wells; Gloria E. Westney; Kendra A. Young; Edwin K. Silverman; Mei Lan K. Han; Barry J. Make

doi:10.1016/j.chest.2019.04.135

Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study

Diego J. Maselli, Surya P. Bhatt, Antonio Anzueto, Russell P. Bowler, Dawn L. DeMeo, Alejandro A. Diaz, Mark T. Dransfield, Ashraf Fawzy, Marilyn G. Foreman, Nicola A. Hanania, Craig P. Hersh, Victor Kim, Gregory L. Kinney, Nirupama Putcha, Emily S. Wan, J. Michael Wells, Gloria E. Westney, Kendra A. Young, Edwin K. Silverman, Mei Lan K. HanBarry J. Make

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

The Genetic Epidemiology of COPD (COPDGene) study is a noninterventional, multicenter, longitudinal analysis of > 10,000 subjects, including smokers with a ≥ 10 pack-year history with and without COPD and healthy never smokers. The goal was to characterize disease-related phenotypes and explore associations with susceptibility genes. The subjects were extensively phenotyped with the use of comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling. The objective of this review was to summarize the major advances in the clinical epidemiology of COPD from the first 10 years of the COPDGene study. We highlight the influence of age, sex, and race on the natural history of COPD, and the impact of comorbid conditions, chronic bronchitis, exacerbations, and asthma/COPD overlap.

Original language	English (US)
Pages (from-to)	228-238
Number of pages	11
Journal	Chest
Volume	156
Issue number	2
DOIs	https://doi.org/10.1016/j.chest.2019.04.135
State	Published - Aug 2019
Externally published	Yes

Keywords

COPD
COPDGene
chronic bronchitis
comorbidities
epidemiology
sex

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.chest.2019.04.135

Cite this

Maselli, D. J., Bhatt, S. P., Anzueto, A., Bowler, R. P., DeMeo, D. L., Diaz, A. A., Dransfield, M. T., Fawzy, A., Foreman, M. G., Hanania, N. A., Hersh, C. P., Kim, V., Kinney, G. L., Putcha, N., Wan, E. S., Wells, J. M., Westney, G. E., Young, K. A., Silverman, E. K., ... Make, B. J. (2019). Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. Chest, 156(2), 228-238. https://doi.org/10.1016/j.chest.2019.04.135

Clinical Epidemiology of COPD : Insights From 10 Years of the COPDGene Study. / Maselli, Diego J.; Bhatt, Surya P.; Anzueto, Antonio; Bowler, Russell P.; DeMeo, Dawn L.; Diaz, Alejandro A.; Dransfield, Mark T.; Fawzy, Ashraf; Foreman, Marilyn G.; Hanania, Nicola A.; Hersh, Craig P.; Kim, Victor; Kinney, Gregory L.; Putcha, Nirupama; Wan, Emily S.; Wells, J. Michael; Westney, Gloria E.; Young, Kendra A.; Silverman, Edwin K.; Han, Mei Lan K.; Make, Barry J.

In: Chest, Vol. 156, No. 2, 08.2019, p. 228-238.

Research output: Contribution to journal › Review article › peer-review

Maselli, DJ, Bhatt, SP, Anzueto, A, Bowler, RP, DeMeo, DL, Diaz, AA, Dransfield, MT, Fawzy, A, Foreman, MG, Hanania, NA, Hersh, CP, Kim, V, Kinney, GL, Putcha, N, Wan, ES, Wells, JM, Westney, GE, Young, KA, Silverman, EK, Han, MLK & Make, BJ 2019, 'Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study', Chest, vol. 156, no. 2, pp. 228-238. https://doi.org/10.1016/j.chest.2019.04.135

Maselli, Diego J. ; Bhatt, Surya P. ; Anzueto, Antonio ; Bowler, Russell P. ; DeMeo, Dawn L. ; Diaz, Alejandro A. ; Dransfield, Mark T. ; Fawzy, Ashraf ; Foreman, Marilyn G. ; Hanania, Nicola A. ; Hersh, Craig P. ; Kim, Victor ; Kinney, Gregory L. ; Putcha, Nirupama ; Wan, Emily S. ; Wells, J. Michael ; Westney, Gloria E. ; Young, Kendra A. ; Silverman, Edwin K. ; Han, Mei Lan K. ; Make, Barry J. / Clinical Epidemiology of COPD : Insights From 10 Years of the COPDGene Study. In: Chest. 2019 ; Vol. 156, No. 2. pp. 228-238.

@article{69ab75a59b5d485db362fa06590adb23,

title = "Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study",

abstract = "The Genetic Epidemiology of COPD (COPDGene) study is a noninterventional, multicenter, longitudinal analysis of > 10,000 subjects, including smokers with a ≥ 10 pack-year history with and without COPD and healthy never smokers. The goal was to characterize disease-related phenotypes and explore associations with susceptibility genes. The subjects were extensively phenotyped with the use of comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling. The objective of this review was to summarize the major advances in the clinical epidemiology of COPD from the first 10 years of the COPDGene study. We highlight the influence of age, sex, and race on the natural history of COPD, and the impact of comorbid conditions, chronic bronchitis, exacerbations, and asthma/COPD overlap.",

keywords = "COPD, COPDGene, chronic bronchitis, comorbidities, epidemiology, sex",

author = "Maselli, {Diego J.} and Bhatt, {Surya P.} and Antonio Anzueto and Bowler, {Russell P.} and DeMeo, {Dawn L.} and Diaz, {Alejandro A.} and Dransfield, {Mark T.} and Ashraf Fawzy and Foreman, {Marilyn G.} and Hanania, {Nicola A.} and Hersh, {Craig P.} and Victor Kim and Kinney, {Gregory L.} and Nirupama Putcha and Wan, {Emily S.} and Wells, {J. Michael} and Westney, {Gloria E.} and Young, {Kendra A.} and Silverman, {Edwin K.} and Han, {Mei Lan K.} and Make, {Barry J.}",

note = "Funding Information: Other contributions: The authors would like to acknowledge the generous support to the COPDGene study (NCT00608764) from the National Heart, Lung, and Blood Institute (Grant U01 HL089897 and U01 HL089856 ) and the support of the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. J. M. reports consulting fees for GlaxoSmithKline, Sunovion, Sanofi/Regeneron, AstraZeneca, and Novartis. A. A. reports consultancy for Boehringer Ingelheim, AstraZeneca, Novartis, and Sunovion. S. P. B. is supported by the National Institutes of Health (NIH) [K23HL133438] and has received research grants from AstraZeneca and ProterixBio. R. P. B. reports consulting fees for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. D. L. D. reports consulting fees from Novartis and grants from the NIH. A. A. D. reports research grants from the NIH and Brigham and Women{\textquoteright}s Hospital; and personal fees from Novartis. M. T. D. has received grant support from the NIH and Department of Defense; consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, and GlaxoSmithKline; and contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, PneumRx/BTG, Pulmonx, and Yungjin. N. A. H. reports consulting fees for Roche, Teva, Sanofi, Boehringer Ingelheim, and Novartis; and research support from Chiesi, Boehringer Ingelheim, GlaxoSmithKline, and Roche. C. P. H. reports consulting fees from AstraZeneca, Concert Pharmaceuticals, Mylan, and 23andMe; and research grants from Boehringer Ingelheim and Novartis. V. K. reports grants from the NHLBI; and consulting fees from Medscape, CSA Medical, AstraZeneca, Concert Pharmaceuticals, the American Board of Internal Medicine, and Gala Therapeutics. N. P. is supported by the NIH/NHLBI [K23HL123594]. J. M. W. reports grants from the NIH/NHLBI [K08HL123940], the Cystic Fibrosis Foundation [SORCH15RO], Bayer AG, and UAB Health Services Foundation; and consulting fees from Quintiles, GlaxoSmithKline, Mereo BioPharma, and Mylan. E. K. S. reports grants from the NIH; personal fees from Novartis; and grant and travel support from GlaxoSmithKline. M. K. H. reports support from the NIH, and the COPD Foundation; consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, and Sunovion; and research support by the NIH/NHLBI, Novartis, and Sunovion. B. J. M. reports grants and personal fees from the NHLBI, AstraZeneca, Spiration, Sunovion, Novartis, CSL Behring, Verona, Boehringer Ingelheim, Theravance, and Circassia; and support for Continuing Medical Education activities from Consensus Medical Education, Integrity Medical Education, Mt. Sinai Medical Center, WebMD, UpToDate, National Jewish Health, SPIRE Learning, the American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, Peer Review Institute, Cleveland Clinic, Medscape, and Ult Medical Academy. Nothing declared (A. F., M. G. F., G. L. K., E. S. W., G. E. W., K. A. Y.). Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. J. M. reports consulting fees for GlaxoSmithKline, Sunovion, Sanofi/Regeneron, AstraZeneca, and Novartis. A. A. reports consultancy for Boehringer Ingelheim, AstraZeneca, Novartis, and Sunovion. S. P. B. is supported by the National Institutes of Health (NIH) [K23HL133438] and has received research grants from AstraZeneca and ProterixBio. R. P. B. reports consulting fees for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. D. L. D. reports consulting fees from Novartis and grants from the NIH. A. A. D. reports research grants from the NIH and Brigham and Women's Hospital; and personal fees from Novartis. M. T. D. has received grant support from the NIH and Department of Defense; consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, and GlaxoSmithKline; and contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, PneumRx/BTG, Pulmonx, and Yungjin. N. A. H. reports consulting fees for Roche, Teva, Sanofi, Boehringer Ingelheim, and Novartis; and research support from Chiesi, Boehringer Ingelheim, GlaxoSmithKline, and Roche. C. P. H. reports consulting fees from AstraZeneca, Concert Pharmaceuticals, Mylan, and 23andMe; and research grants from Boehringer Ingelheim and Novartis. V. K. reports grants from the NHLBI; and consulting fees from Medscape, CSA Medical, AstraZeneca, Concert Pharmaceuticals, the American Board of Internal Medicine, and Gala Therapeutics. N. P. is supported by the NIH/NHLBI [K23HL123594]. J. M. W. reports grants from the NIH/NHLBI [K08HL123940], the Cystic Fibrosis Foundation [SORCH15RO], Bayer AG, and UAB Health Services Foundation; and consulting fees from Quintiles, GlaxoSmithKline, Mereo BioPharma, and Mylan. E. K. S. reports grants from the NIH; personal fees from Novartis; and grant and travel support from GlaxoSmithKline. M. K. H. reports support from the NIH, and the COPD Foundation; consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, and Sunovion; and research support by the NIH/NHLBI, Novartis, and Sunovion. B. J. M. reports grants and personal fees from the NHLBI, AstraZeneca, Spiration, Sunovion, Novartis, CSL Behring, Verona, Boehringer Ingelheim, Theravance, and Circassia; and support for Continuing Medical Education activities from Consensus Medical Education, Integrity Medical Education, Mt. Sinai Medical Center, WebMD, UpToDate, National Jewish Health, SPIRE Learning, the American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, Peer Review Institute, Cleveland Clinic, Medscape, and Ult Medical Academy. Nothing declared (A. F. M. G. F. G. L. K. E. S. W. G. E. W. K. A. Y.). Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Other contributions: The authors would like to acknowledge the generous support to the COPDGene study (NCT00608764) from the National Heart, Lung, and Blood Institute (Grant U01 HL089897 and U01 HL089856) and the support of the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. FUNDING/SUPPORT: This research was supported by the National Heart, Lung, and Blood Institute [Grants U01 HL089897 and U01 HL089856]. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = aug,

doi = "10.1016/j.chest.2019.04.135",

language = "English (US)",

volume = "156",

pages = "228--238",

journal = "Diseases of the chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "2",

}

TY - JOUR

T1 - Clinical Epidemiology of COPD

T2 - Insights From 10 Years of the COPDGene Study

AU - Maselli, Diego J.

AU - Bhatt, Surya P.

AU - Anzueto, Antonio

AU - Bowler, Russell P.

AU - DeMeo, Dawn L.

AU - Diaz, Alejandro A.

AU - Dransfield, Mark T.

AU - Fawzy, Ashraf

AU - Foreman, Marilyn G.

AU - Hanania, Nicola A.

AU - Hersh, Craig P.

AU - Kim, Victor

AU - Kinney, Gregory L.

AU - Putcha, Nirupama

AU - Wan, Emily S.

AU - Wells, J. Michael

AU - Westney, Gloria E.

AU - Young, Kendra A.

AU - Silverman, Edwin K.

AU - Han, Mei Lan K.

AU - Make, Barry J.

N1 - Funding Information: Other contributions: The authors would like to acknowledge the generous support to the COPDGene study (NCT00608764) from the National Heart, Lung, and Blood Institute (Grant U01 HL089897 and U01 HL089856 ) and the support of the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. J. M. reports consulting fees for GlaxoSmithKline, Sunovion, Sanofi/Regeneron, AstraZeneca, and Novartis. A. A. reports consultancy for Boehringer Ingelheim, AstraZeneca, Novartis, and Sunovion. S. P. B. is supported by the National Institutes of Health (NIH) [K23HL133438] and has received research grants from AstraZeneca and ProterixBio. R. P. B. reports consulting fees for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. D. L. D. reports consulting fees from Novartis and grants from the NIH. A. A. D. reports research grants from the NIH and Brigham and Women’s Hospital; and personal fees from Novartis. M. T. D. has received grant support from the NIH and Department of Defense; consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, and GlaxoSmithKline; and contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, PneumRx/BTG, Pulmonx, and Yungjin. N. A. H. reports consulting fees for Roche, Teva, Sanofi, Boehringer Ingelheim, and Novartis; and research support from Chiesi, Boehringer Ingelheim, GlaxoSmithKline, and Roche. C. P. H. reports consulting fees from AstraZeneca, Concert Pharmaceuticals, Mylan, and 23andMe; and research grants from Boehringer Ingelheim and Novartis. V. K. reports grants from the NHLBI; and consulting fees from Medscape, CSA Medical, AstraZeneca, Concert Pharmaceuticals, the American Board of Internal Medicine, and Gala Therapeutics. N. P. is supported by the NIH/NHLBI [K23HL123594]. J. M. W. reports grants from the NIH/NHLBI [K08HL123940], the Cystic Fibrosis Foundation [SORCH15RO], Bayer AG, and UAB Health Services Foundation; and consulting fees from Quintiles, GlaxoSmithKline, Mereo BioPharma, and Mylan. E. K. S. reports grants from the NIH; personal fees from Novartis; and grant and travel support from GlaxoSmithKline. M. K. H. reports support from the NIH, and the COPD Foundation; consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, and Sunovion; and research support by the NIH/NHLBI, Novartis, and Sunovion. B. J. M. reports grants and personal fees from the NHLBI, AstraZeneca, Spiration, Sunovion, Novartis, CSL Behring, Verona, Boehringer Ingelheim, Theravance, and Circassia; and support for Continuing Medical Education activities from Consensus Medical Education, Integrity Medical Education, Mt. Sinai Medical Center, WebMD, UpToDate, National Jewish Health, SPIRE Learning, the American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, Peer Review Institute, Cleveland Clinic, Medscape, and Ult Medical Academy. Nothing declared (A. F., M. G. F., G. L. K., E. S. W., G. E. W., K. A. Y.). Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. J. M. reports consulting fees for GlaxoSmithKline, Sunovion, Sanofi/Regeneron, AstraZeneca, and Novartis. A. A. reports consultancy for Boehringer Ingelheim, AstraZeneca, Novartis, and Sunovion. S. P. B. is supported by the National Institutes of Health (NIH) [K23HL133438] and has received research grants from AstraZeneca and ProterixBio. R. P. B. reports consulting fees for Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. D. L. D. reports consulting fees from Novartis and grants from the NIH. A. A. D. reports research grants from the NIH and Brigham and Women's Hospital; and personal fees from Novartis. M. T. D. has received grant support from the NIH and Department of Defense; consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, and GlaxoSmithKline; and contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, PneumRx/BTG, Pulmonx, and Yungjin. N. A. H. reports consulting fees for Roche, Teva, Sanofi, Boehringer Ingelheim, and Novartis; and research support from Chiesi, Boehringer Ingelheim, GlaxoSmithKline, and Roche. C. P. H. reports consulting fees from AstraZeneca, Concert Pharmaceuticals, Mylan, and 23andMe; and research grants from Boehringer Ingelheim and Novartis. V. K. reports grants from the NHLBI; and consulting fees from Medscape, CSA Medical, AstraZeneca, Concert Pharmaceuticals, the American Board of Internal Medicine, and Gala Therapeutics. N. P. is supported by the NIH/NHLBI [K23HL123594]. J. M. W. reports grants from the NIH/NHLBI [K08HL123940], the Cystic Fibrosis Foundation [SORCH15RO], Bayer AG, and UAB Health Services Foundation; and consulting fees from Quintiles, GlaxoSmithKline, Mereo BioPharma, and Mylan. E. K. S. reports grants from the NIH; personal fees from Novartis; and grant and travel support from GlaxoSmithKline. M. K. H. reports support from the NIH, and the COPD Foundation; consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, and Sunovion; and research support by the NIH/NHLBI, Novartis, and Sunovion. B. J. M. reports grants and personal fees from the NHLBI, AstraZeneca, Spiration, Sunovion, Novartis, CSL Behring, Verona, Boehringer Ingelheim, Theravance, and Circassia; and support for Continuing Medical Education activities from Consensus Medical Education, Integrity Medical Education, Mt. Sinai Medical Center, WebMD, UpToDate, National Jewish Health, SPIRE Learning, the American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, Peer Review Institute, Cleveland Clinic, Medscape, and Ult Medical Academy. Nothing declared (A. F. M. G. F. G. L. K. E. S. W. G. E. W. K. A. Y.). Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Other contributions: The authors would like to acknowledge the generous support to the COPDGene study (NCT00608764) from the National Heart, Lung, and Blood Institute (Grant U01 HL089897 and U01 HL089856) and the support of the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. FUNDING/SUPPORT: This research was supported by the National Heart, Lung, and Blood Institute [Grants U01 HL089897 and U01 HL089856]. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. Publisher Copyright: © 2019

PY - 2019/8

Y1 - 2019/8

N2 - The Genetic Epidemiology of COPD (COPDGene) study is a noninterventional, multicenter, longitudinal analysis of > 10,000 subjects, including smokers with a ≥ 10 pack-year history with and without COPD and healthy never smokers. The goal was to characterize disease-related phenotypes and explore associations with susceptibility genes. The subjects were extensively phenotyped with the use of comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling. The objective of this review was to summarize the major advances in the clinical epidemiology of COPD from the first 10 years of the COPDGene study. We highlight the influence of age, sex, and race on the natural history of COPD, and the impact of comorbid conditions, chronic bronchitis, exacerbations, and asthma/COPD overlap.

AB - The Genetic Epidemiology of COPD (COPDGene) study is a noninterventional, multicenter, longitudinal analysis of > 10,000 subjects, including smokers with a ≥ 10 pack-year history with and without COPD and healthy never smokers. The goal was to characterize disease-related phenotypes and explore associations with susceptibility genes. The subjects were extensively phenotyped with the use of comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling. The objective of this review was to summarize the major advances in the clinical epidemiology of COPD from the first 10 years of the COPDGene study. We highlight the influence of age, sex, and race on the natural history of COPD, and the impact of comorbid conditions, chronic bronchitis, exacerbations, and asthma/COPD overlap.

KW - COPD

KW - COPDGene

KW - chronic bronchitis

KW - comorbidities

KW - epidemiology

KW - sex

UR - http://www.scopus.com/inward/record.url?scp=85069679266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069679266&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2019.04.135

DO - 10.1016/j.chest.2019.04.135

M3 - Review article

C2 - 31154041

AN - SCOPUS:85069679266

VL - 156

SP - 228

EP - 238

JO - Diseases of the chest

JF - Diseases of the chest

SN - 0012-3692

IS - 2

ER -

Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this